ModifiedUnitedHealthcarePolicy CS149KS.02

Pharmacogenetic Panel Testing (for Kansas Only)

This Kansas-specific medical policy governs coverage and clinical criteria for pharmacogenetic multi-gene panel testing (panels of five or more genes) and related CPT/HCPCS codes for UnitedHealthcare members in Kansas.

Policy Summary

PayerUnitedHealthcare

PolicyPharmacogenetic Panel Testing (for Kansas Only)

Policy CodePolicy CS149KS.02

Change TypeModified — added InterQual cross-reference

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionRefer to InterQual® CP: Molecular Diagnostics, Pharmacogenomic Testing for Psychotropic Medication Drug Response when determining medical necessity for pharmacogenetic testing for psychotropic medications.

SourceLink

POLICY UPDATE CHANGES

Added instruction to refer to the InterQual® CP: Molecular Diagnostics, Pharmacogenomic Testing for Psychotropic Medication Drug Response for medical necessity clinical coverage criteria for pharmacogenetic testing.

Archived previous policy version CS149KS.01.

5+ genesMulti-Gene threshold

6 genesCPT 81418 requirement

1,944Oslin RCT size

42%Genetic variance (MDD)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

13Psych trials in review

1New InterQual cross-ref

Coverage Criteria

Not Medically Necessary — Multi-Gene Panels

Not medically necessary for any indication: The use of pharmacogenetic Multi-Gene Panels (five or more genes) for the evaluation of drug‑metabolizer status is unproven and not medically necessary for any indication due to insufficient evidence of efficacy.5+ genes

Applies to multi‑gene panels as defined in policy; see InterQual for molecular diagnostics guidance.

Psychiatric indications

Covered when evidence supports clinical utility in similar trial contexts (examples below reflect populations where benefit was observed):

Adults with MDD initiating or switching antidepressant therapy: Adults with major depressive disorder (MDD) who are initiating or switching antidepressant therapy and/or have had prior inadequate response to antidepressants; randomized trials and meta‑analysis reported modest increases in remission/response and reduced prescriptions with PGx‑guided care (e.g., Oslin et al., GUIDED, NeuroIDgenetix).Prior failed medication trials common in trials (mean ~3 in GUIDED)

Effect sizes modest; benefits may be early and not always sustained to 24 weeks; many trials used proprietary algorithms and variable panels.

Other psychiatric indications evaluated in trials: Patients with depression or anxiety enrolled in RCTs (including those new to treatment or inadequately controlled) showed greater response/remission at intermediate timepoints when clinicians had access to PGx results compared with treatment as usual in several studies, though heterogeneity exists across studies and algorithms.

Clinical application should follow InterQual criteria where applicable.

Cardiovascular indications

Covered only in contexts where actionable, guideline‑established single‑gene results are needed or within research protocols; multigene panel coverage remains investigational for routine use:

Cardiovascular PGx use for immediate management: PGx testing may be considered when a validated, actionable single‑gene result (for example, CYP2C19 genotype to guide antiplatelet therapy after PCI) is required to guide immediate inpatient or outpatient management.Use limited to guideline‑supported gene‑drug pairs

Panel‑based testing for broad cardiovascular risk prediction or routine multigene panels is not supported by high‑quality outcome data.

Panel testing for cardiovascular indications: Routine multigene pharmacogenomic panel testing for cardiovascular disease management is considered investigational/not supported due to limited high‑quality evidence and mixed real‑world outcomes.

Simulations suggest prescribing opportunities but claims analyses did not show improved clinical outcomes.

Anthracycline cardiotoxicity

Not routinely covered for prediction of chemotherapy‑induced cardiotoxicity outside of research protocols

Anthracycline cardiotoxicity testing: Pharmacogenomic testing to predict anthracycline‑associated cardiotoxicity (ACT) is exploratory: multiple variants and genes have been associated with CIC in systematic reviews and cohort studies, but results are inconsistent and require further validation across age groups and settings.none

Routine clinical use of panels for ACT risk stratification is not supported; further prospective, long‑term studies are needed.

Coverage logic for PGx panels and PrismRA

General coverage approach for PGx multi‑gene panel testing based on available evidence:

Guideline‑backed single‑gene testing: When gene‑drug pairs have established guideline or CPIC‑level clinical actionability (for example, CYP2D6 and CYP2C19 for certain antidepressants), targeted testing of those specific genes per guideline recommendations may be considered medically necessary to inform drug selection and dosing.CPIC or equivalent guideline support

STRIPE and CPIC identify clinically actionable gene‑drug pairs; no endorsement is provided for multi‑gene panels of five or more genes absent guideline support.

Multi‑gene panels for broad indications: Use of PGx multi‑gene panel testing for multimorbidity, polypharmacy, general medication prescribing, IBD, cancer treatment toxicity prediction, and similar broad indications is considered to have insufficient evidence to establish clinical utility at this time.insufficient evidence

Although some RCTs (e.g., PREPARE) and implementation studies show potential, heterogeneity limits broad endorsement of panels ≥5 genes.

Pharmacogenetic testing — psychotropic medication (InterQual cross-reference)

Coverage rationale updated to incorporate external InterQual criteria

InterQual‑referenced psychotropic PGx criteria: Medical necessity determinations for pharmacogenetic testing to guide psychotropic medication drug response shall follow the InterQual® CP: Molecular Diagnostics, Pharmacogenomic Testing for Psychotropic Medication Drug Response criteria.

Providers and reviewers must apply InterQual rules where applicable and verify federal/state/contractual benefit terms.

The PrismRA molecular signature response classifier (MSRC) developed by Scipher Medicine is considered unproven and not medically necessary for predicting inadequate response to anti‑TNF therapies in rheumatoid arthritis. Assessments identified a very low‑quality body of evidence, changes in test categorizations and cutoffs, and reliance on modeling rather than prospective trial validation; therefore current evidence is insufficient to establish clinical utility for directing initial biologic selection outside investigational or evidence‑development contexts. Documentation of the PrismRA modeling assumptions and the lack of completed prospective trial validation should be considered when reviewing requests for PrismRA‑guided treatment decisions.

Tests or components that lack demonstrated analytic or clinical validity, or that rely on proprietary algorithms without transparent, reproducible evidence, are not considered validated for routine clinical decision making. Systematic reviews and trial reports note that many commercial panels include genes (e.g., SLC6A4, HTR2A) for which dosing guidance is unavailable and that proprietary algorithms can produce conflicting recommendations; such limitations reduce generalizability and support for coverage.

Routine use of multi‑gene pharmacogenomic panels to predict treatment response, adverse effects, risk of dependence, or to improve overall outcomes in pain management is not supported by current peer‑reviewed evidence. Systematic reviews and utility evaluations (including Hayes assessments) found limited, low‑quality or inconsistent data for PGx‑guided opioid or chronic pain management, and randomized studies are few and heterogeneous.

The evidence base for the PrismRA test is limited: independent assessments rated the evidence as very low quality and noted that the test definitions and cutoffs have changed across analyses. Additional larger, independent studies with improved designs — including prospective clinical trial validation of predictive accuracy and demonstration of impact on patient‑centered outcomes — are required before PrismRA can be considered to have established clinical utility.

Broad application of pharmacogenomic multi‑gene panels for multimorbidity, polypharmacy, cancer treatment toxicity prediction, inflammatory bowel disease (IBD), and general medication prescribing is considered unsupported at this time due to insufficient evidence of clinical benefit. Real‑world claims analyses and systematic reviews have not consistently demonstrated improved outcomes with broad panel testing and therefore routine coverage for these broad indications is not established.

FDA clearance or approval of a genetic test is provided for informational purposes and does not by itself establish coverage. Coverage determinations require that the test meet applicable medical necessity criteria and relevant contractual, federal and state requirements.

Pharmacogenetic multi‑gene panels that include five or more genes are considered unproven and not medically necessary for any indication based on current evidence insufficiency for broad clinical utility.

Routine ordering of multigene PGx panels for cardiovascular disease management or for mental health conditions is not supported unless specific, guideline‑backed, single‑gene actionable results are required for decision making. High‑quality outcome studies for multigene panels in cardiovascular settings are lacking; conversely, CPIC guidance supports targeted testing of specific genes (e.g., CYP2C19, CYP2D6) where evidence and dosing recommendations exist.

Hayes evaluations and systematic reviews found insufficient or low‑quality evidence to support routine pharmacogenomic testing for prediction of opioid dependence or to improve opioid‑related treatment outcomes. Consequently, routine PGx‑guided opioid prescribing is not supported at present.

Routine ordering of multi‑gene panels (≥ five genes) for general prescribing without clear, guideline‑supported gene‑drug actionability is not medically necessary. Many psychiatry trials that demonstrated modest benefit enrolled difficult‑to‑treat cohorts with prior medication failures; broad pre‑emptive panel testing in unselected populations lacks supportive evidence.

Tests cannot be covered solely on the basis of FDA approval/clearance; regulatory status is informational only. Coverage requires that the test meet applicable medical necessity criteria (for example, InterQual® criteria where referenced) and any contractual or state‑specific requirements.

Major depressive disorder (MDD) in adults initiating or switching antidepressant therapy, particularly those with prior inadequate response

Clinical trial contexts where benefit was observed — use after prior medication failures or when initiating/switching therapy:

MDD — initiation or switching antidepressant therapy: Adults with major depressive disorder (MDD) initiating or switching antidepressant therapy, particularly those with prior inadequate response to antidepressants, as studied in RCTs (e.g., Oslin et al., GUIDED), may be appropriate candidates for PGx testing when results would influence medication selection.Many trials enrolled patients with ≥1 prior failed antidepressant; GUIDED mean ~3 failed medications

Document prior treatment history and intended management changes; InterQual criteria should also be applied.

Investigational/early evidence: pharmacogenomic variants associated with anthracycline-associated cardiotoxicity (ACT)

Investigational/early evidence — not sufficient for routine coverage:

Variants associated with ACT: Multiple genomic variants have been associated with anthracycline‑associated cardiotoxicity (ACT) in systematic reviews and cohort studies (e.g., CYBA rs4673, RAC2 rs13058338, CYP3A5 rs776746, ABCC1 rs45511401, ABCC2 rs8187710, HER2‑Ile655Val rs1136201), but findings are inconsistent and require further prospective validation.none

Routine clinical use of testing for ACT risk stratification is not supported outside research protocols.

Perioperative or postoperative pain management tailoring (total joint arthroplasty / TKA) evidence mixed

Evidence mixed; some small RCTs show benefit while others do not — interpret cautiously.

Perioperative/postoperative pain management (TKA/arthroplasty): PGx‑guided medication selection for perioperative or postoperative pain management has mixed evidence: a small TKA RCT found no difference, while a hip/knee arthroplasty RCT reported reduced pain and opioid consumption with PGx‑guided prescribing.

Study sizes are limited; further research is needed to define target populations who may benefit.

Rheumatoid arthritis — PrismRA / MSRC testing to predict non-response to anti-TNF agents and guide biologic selection

PrismRA (MSRC) shows early cohort and modeling evidence but lacks high‑quality randomized trial validation:

PrismRA — provider impact and outcomes: Studies report that PrismRA/MSRC results informed treatment selection and were associated with improved short‑term outcomes in observational cohorts; decision‑analytic models project potential clinical and economic benefit but are based on assumptions requiring prospective validation.

Insurance coverage concerns limited alignment with MSRC recommendations in some studies; confirm prior authorization/coverage before using results to change therapy.

PrismRA — recommendation: PrismRA is considered investigational for directing initial biologic selection to avoid anti‑TNF therapy; routine coverage for this purpose is not supported until prospective randomized evidence is available.

Evidence limitations include potential bias, limited external controls, and lack of randomized comparison.

Testing of specific gene-drug pairs with guideline-backed clinical actionability (e.g., CYP2D6, CYP2C19 for antidepressants)

Targeted testing of specific, guideline‑actionable gene‑drug pairs may be appropriate when CPIC or equivalent recommendations exist:

Guideline‑actionable gene‑drug pairs: Testing of individual genes with guideline‑backed clinical actionability (for example CYP2D6 and CYP2C19 for antidepressants) to inform drug selection and dosing is appropriate when supported by CPIC or equivalent guidance.CPIC or equivalent guideline support

CPIC updates and STRIPE reviews identify clinically actionable pairs; no CPIC recommendations endorse multi‑gene panels ≥5 genes per se.

Pharmacogenomic testing to guide psychotropic medication drug response where InterQual criteria are met

Pharmacogenomic testing to guide psychotropic medication drug response is covered only when InterQual criteria are met and applied:

InterQual applies for psychotropic PGx testing: Medical necessity for pharmacogenomic testing to guide psychotropic medication drug response is determined by InterQual® CP criteria; providers and reviewers must apply InterQual rules and document clinical context and prior treatment trials as specified by InterQual.

UnitedHealthcare uses InterQual as the primary criteria set for non‑state‑specific clinical determinations.

Coding

Applicable CPT/HCPCS Codesmixed

0029U	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (i.e., CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823).
0173U	Psychiatry (i.e., depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes.
0175U	Psychiatry (e.g., depression, anxiety), genomic analysis panel, variant analysis of 15 genes.
0345U	Psychiatry [e.g., depression, anxiety, attention deficit hyperactivity disorder (ADHD)], genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6.
0347U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes.
0348U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes.
0349U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions.
0350U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes.
0392U	Drug metabolism [depression, anxiety, attention deficit hyperactivity disorder (ADHD)], gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6.
0411U	Psychiatry [e.g., depression, anxiety, attention deficit hyperactivity disorder (ADHD)], genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6.

1–10 of 22

1/3

No explicit CPT/HCPCS/ICD codes in this document segmentmixed

No codes listed

No explicit CPT/HCPCS/ICD codes in this document segmentmixed

No codes listed

Multi-Gene Panel definition / CPT 81418 gene minimum

Multi-Gene Panel thresholdDefined as panels that include five or more genes (policy definition).

CPT 81418 requirementCPT 81418 describes a genomic sequence analysis panel that must include testing of at least 6 genes, and must include CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis.

Alternative terminologyAlso called multigene test, multiple-gene panel test, and multiple-gene test (National Cancer Institute definition).

Prior medication failures (trial context details)

Typical prior medication history in trialsMany psychiatric PGx trials enrolled patients with inadequate response to at least one antidepressant; GUIDED cohort average was ~3 failed medications (difficult-to-treat population).

Provider Actions & Prior Authorization

Billing Rule

Code listing and prior authorization reference

Applicable codes listed in this policy are provided for reference only and do not guarantee coverage or payment. Providers should reference the payer-specific code lists and prior authorization (PA) resources when submitting requests. For certain pharmacogenetic tests and molecular diagnostics, prior authorization may be required.

Confirm applicable CPT/HCPCS/ICD-10 codes with UnitedHealthcare provider resources before ordering.
Listing of a code in this policy does not imply the service is covered.

Prior Authorization

Prior authorization for cardiovascular PGx testing

Prior authorization is generally required for pharmacogenetic testing related to cardiovascular disease risk or management when multi-gene panels or testing beyond guideline-recommended single-gene assays are requested. Providers should consult UnitedHealthcare’s cardiovascular PGx coverage resources and submit clinical rationale and relevant documentation with PA requests.

Not Covered

Multi‑gene pharmacogenetic panels (five or more genes) are designated not medically necessary for any indication under this policy because current evidence does not establish consistent clinical benefit across targeted indications and panel compositions. Claims and observational data have not uniformly shown improved outcomes and some analyses suggest potential adverse signals in real‑world cohorts.

The PrismRA molecular signature test for predicting inadequate response to anti‑TNF therapy in rheumatoid arthritis remains unproven and not medically necessary due to limited and low‑quality evidence, evolving test classification thresholds, and absence of definitive prospective trial validation demonstrating improved patient outcomes when care is guided by the assay.

Routine multigene panel testing to predict anthracycline‑induced cardiotoxicity is not supported outside research protocols. Although meta‑analyses have identified variants potentially associated with cardiotoxicity, findings are inconsistent across age groups and require further prospective validation before clinical implementation.

Routine multi‑gene PGx panel testing for pain management to predict treatment response, dependence, or to improve overall outcomes is not supported. Systematic reviews cite limited, heterogeneous studies and Hayes evaluations report insufficient evidence for routine clinical adoption.

Use of PGx multi‑gene panels for broad, non‑guideline–specific indications (such as multimorbidity, polypharmacy, or general medication prescribing) lacks sufficient evidence and is therefore not supported for routine use.

Modeling studies and early performance metrics for PrismRA exist, and some decision‑analytic models suggest potential benefit when test results are followed, but prospective randomized trial validation of PrismRA‑directed strategies is ongoing. Coverage based solely on modeling or preliminary performance estimates is not justified without confirmatory clinical trial evidence.

Definitions

Multi-Gene Panel definition

Definition of Multi-Gene PanelGenetic tests that use next-generation sequencing to test multiple genes simultaneously (also called multigene test, multiple-gene panel test, and multiple-gene test).

Scope in this policyPolicy focuses on multi-gene panel testing (pharmacogenomics) distinguishing from single-gene or targeted tests used for specific drugs.

Minimum panel size for policy considerationMulti-gene panels of five or more genes are the primary focus of the policy's coverage and not-medically-necessary determinations.

Combinatorial pharmacogenomic testing

Combinatorial PGx testing definedTesting that combines genotypes from multiple genes into an integrated report or algorithm (often proprietary) to guide psychotropic medication selection and dosing.

Proprietary algorithms caution

Covered Indications / Eligibility

Eligibility Requirements

No eligibility requirement nodes are specified in this excerpt.

Background

Pharmacogenetics studies how genetic variation influences individual medication response and may inform targeted drug selection or dosing. Targeted single‑gene tests with established guideline actionability (for example, CYP2C19 or CYP2D6 for specific drugs) differ from pre‑emptive multi‑gene panels. Laboratories that perform genetic testing are regulated under CLIA, and FDA clearance/approval of tests is informational and not sufficient alone for coverage determinations.

Revision History

2026-03-01policy_revisionLatest

2026-03-01archival

Archived previous policy version CS149KS.01.

Policy Summary

PayerUnitedHealthcare

PolicyPharmacogenetic Panel Testing (for Kansas Only)

Policy CodePolicy CS149KS.02

Change TypeModified — added InterQual cross-reference

Effective DateMar 1, 2026

Next Review DateN/A

SourceLink

On This Page

PrismRA (MSRC) testing: PrismRA (MSRC) demonstrates early performance and decision‑analytic modeling suggesting potential benefit in guiding biologic selection for RA, but lacks prospective randomized trial validation; routine coverage to direct initial anti‑TNF avoidance is not supported outside investigational or evidence‑development contexts.ongoing validation required

Provider alignment with MSRC was sometimes limited by insurance coverage; confirm prior authorization or coverage before acting on MSRC results.

Trial duration and outcome measures

Trials (e.g., GUIDED) assessed outcomes at scheduled timepoints including 4, 8, 12, and 24 weeks using HAMD-17 and reported response/remission rates.

Use of genotypes to guide prescribingPrescribing recommendations in several trials were based primarily on CYP2C19 and CYP2D6 genotypes, sometimes within proprietary algorithms assessing additional genes.

High-quality evidence for multi-gene PGx testing in cardiovascular settings is limited; PA reviewers may request evidence of clinical impact.
For PCI or antiplatelet decision-making, document specific clinical question and how test results will change management.

Prior Authorization

Confirm coverage / prior authorization for MSRC-guided therapy

Confirm coverage and obtain prior authorization for MSRC/PrismRA-guided therapy prior to ordering. Insurers may require documentation of how the PrismRA or similar test result will be used to select or avoid anti-TNF therapy and evidence that alternative management options were considered.

Document the PrismRA result and the specific treatment decision informed by the result (e.g., selection of non‑TNFi biologic).
If PA is denied due to insufficient evidence, include rationale and any supporting clinical details when appealing.

Prior Authorization

Centralized approval often used

Implementation programs for PGx testing frequently use a centralized review or testing unit to triage and approve test orders. When available, follow the payer’s centralized prior authorization or molecular diagnostics routing process to ensure timely review.

Centralized testing units may classify requests (e.g., pre-emptive screening vs. treatment‑specific) and approve only those fitting defined categories.
Provide clinical context and prior medication history when submitting to a centralized review team.

Denial Risk

Not medically necessary — multi-gene panels (provider action reiteration)

The use of pharmacogenetic multi-gene panels (five or more genes) for assessment of drug-metabolizer status is considered unproven and not medically necessary. Do not submit multi-gene panel orders without prior authorization and clear clinical justification consistent with policy criteria.

Multi-gene panels (≥5 genes) are unproven for most indications and may be denied as not medically necessary.
If ordering single-gene tests with guideline support (e.g., CYP2C19 for clopidogrel), document indication and necessity; avoid broad panels when not warranted.

Denial Risk

Insurance coverage may block use of MSRC-guided therapy

Insurance coverage limitations may prevent use of PrismRA/MSRC-guided therapy even when a test result suggests an alternate treatment. When ordering, obtain PA and be prepared to document why deviation from standard sequencing of biologics is clinically necessary.

In one implementation study, providers reported insurance-related barriers to following PrismRA recommendations in ~62% of deviations.
If insurance restricts coverage of MSRC-guided choices, include clinical notes and prior treatment failures when appealing.

Denial Risk

Insufficient evidence trigger

Insufficient evidence or lack of established clinical utility for a requested test is a common trigger for denial. When requesting coverage for tests with limited evidence, supply strong clinical justification and, where available, peer-reviewed evidence supporting clinical utility for the specific indication.

Tests with low-quality evidence (e.g., PrismRA rated D2 by Hayes) may be denied; supply outcome data or rationale on how testing will alter management.
For novel or proprietary algorithms, provide validation data or references to guideline-endorsed use when available.

Documentation Required

Required clinical outcome documentation

When tests are approved, document clinical outcomes and how the test informed treatment decisions. This documentation supports medical necessity on retrospective review and may be required for PA approval.

For PrismRA/MSRC: record the test result, the specific medication chosen or avoided, and clinical response measures (e.g., ACR50 at 12/24 weeks).
For psychiatric PGx: document prior antidepressant trials, how PGx results changed prescribing, and clinical outcomes (response/remission scores and timing).

Documentation Required

Clinical justification and triage documentation

Provide clear clinical justification and triage documentation when submitting PGx or molecular diagnostic PA requests. Include prior medication history, number and timing of treatment failures, disease activity measures, and the specific management decision that will be informed by the test.

Psychiatric PGx requests: include number of prior antidepressants failed, severity scores, and plan for medication changes based on results.
RA/MSRC requests: include disease activity measures (e.g., DAS28, CDAI), prior DMARD/biologic exposures, and rationale for deviating from standard step-therapy sequencing.

Step Therapy

Step approach for psychiatric PGx testing

A stepwise approach is often appropriate for psychiatric PGx testing: reserve testing for individuals with inadequate response or intolerance to multiple antidepressants rather than first-line use, and document prior treatment history.

Trials showing benefit concentrated in patients who failed up to three prior medications; include this history in PA submissions.
Avoid broad panels that include genes without dosing guidance; focus on CYP2C19 and CYP2D6 when clinically appropriate.

Step Therapy

Step-therapy context for RA biologic selection

When considering PrismRA in RA management, understand that treatment sequencing and step-therapy policies may apply. PrismRA is intended to predict likely non-response to TNFi agents to inform selection of an alternative mechanism of action; document prior DMARD failures and reasoning for choice of biologic.

Payers may require failure of conventional synthetic DMARDs and documentation of active disease (e.g., ACR50 target) before approving biologic selection.
Include prior biologic exposures and reasons for switching when requesting coverage for non‑TNFi selection based on test results.

Documentation Required

RA treatment sequencing considerations

RA treatment sequencing considerations should be documented: state the disease activity measure used, prior therapy history, and anticipated benefit of selecting a specific b/tsDMARD based on the test result.

Record objective disease activity measures (DAS, CDAI, RAPID3, etc.) and prior responses to csDMARDs and biologics.
If using PrismRA to avoid an anti‑TNFi, document why an alternate mechanism is preferred for this patient and expected clinical follow-up schedule.

Note

No explicit step therapy requirements stated

There are no explicit uniform step therapy requirements stated in this policy for all pharmacogenetic tests; local plan or state contractual rules may impose additional step-therapy or prior authorization rules. Always verify plan-level requirements before ordering.

UnitedHealthcare may use InterQual criteria where applicable; failure to reference InterQual criteria when required may delay or result in denial.
Check federal, state, or contractual requirements which govern coverage in case of conflict with this policy.

FDA approval or clearance of a genetic test does not, by itself, establish coverage. The policy treats FDA status as informational and requires medical necessity criteria to be met for coverage decisions.

Many commercial panels use proprietary algorithms that may include genes without dosing guidelines and can produce conflicting recommendations across tests.

Trial applicationCombinatorial approaches were used in psychiatry trials where recommendations incorporated CYP2C19/CYP2D6 plus additional variants or algorithm outputs.

Actionable phenotype definition

Actionable phenotype definitionA genotype-inferred metabolizer or risk status (e.g., CYP2C19 poor metabolizer) that, according to guideline or CPIC-level recommendations, could alter drug selection or dosing.

Prevalence in cardiovascular cohortsIn a PCI cohort compiling five genes (CYP2C19, CYP2D6, CYP2C9, VKORC1, SLCO1B1), 77% had at least one actionable phenotype and 32% had immediate genotype-guided prescribing opportunities.

Guideline linkageActionable phenotypes are those with established CPIC/FDA/other guideline recommendations supporting therapeutic changes rather than exploratory variant findings.

ACT (Anthracycline associated cardiotoxicity) definition

ACT (definition)Anthracycline-associated cardiotoxicity (ACT) — cardiotoxic adverse effects related to anthracycline chemotherapy that can present during therapy or years after treatment.

Evidence statusGenetic associations with ACT are exploratory; multiple SNPs and genes have been reported but require prospective validation before clinical use.

Clinical implicationRoutine PGx panel testing to stratify ACT risk is not supported for clinical care outside research due to inconsistent findings and need for long-term follow-up studies.

PrismRA / MSRC definition

PrismRA / MSRC descriptionPrismRA (molecular signature response classifier, MSRC) is a multi-feature molecular test combining gene expression features, anti-CCP, and clinical metrics to predict likelihood of non-response to anti‑TNF therapy in RA.

Intended useIntended to identify RA patients likely to be poor responders to anti‑TNF therapy and to inform biologic selection decisions in biologic-naïve patients.

Validation statusValidation cohorts and preliminary performance metrics (e.g., reported NPV 92%, TNR 50%) exist, but prospective clinical trial validation is ongoing and evidence remains limited.

PrismRA description

PrismRA test overviewPrismRA (Scipher Medicine) predicts non-response to anti‑TNF therapies using a biomarker panel and clinical features; authors reported preliminary NPV of 92% and TNR of 50%.

Development and validationDevelopment involved cross-cohort, cross-platform studies with discovery, training, and a 175-subject validation cohort; limitations include heterogeneous platforms and cohorts.

Commercialization plansScipher intends to offer PrismRA commercially as a CAP‑proficient, CLIA‑certified laboratory test once trial endpoints are established and validation completed.

CPIC definition

CPIC (organization)Clinical Pharmacogenetics Implementation Consortium (CPIC) is an international organization producing peer-reviewed, evidence-based, updatable gene/drug prescribing guidelines to translate genetic test results into actionable prescribing decisions.

Guideline scopeCPIC provides guidelines for genes such as CYP2D6 and CYP2C19 for antidepressants and tricyclic dosing; CPIC expanded guidance on SSRI dosing and related genes in 2023 updates.

Limitations regarding multi-gene panelsNo existing CPIC guidelines provide recommendations specifically for multi-gene panels that include five or more genes; CPIC addresses specific gene-drug pairs with demonstrated actionability.

CLIA regulation

CLIA regulationLaboratories that perform genetic tests are regulated under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988.

Regulatory implicationGenetic tests provided clinically should be performed in CLIA-regulated laboratories; policy notes labs performing genetic tests must meet CLIA requirements.

Reference linkPolicy cites FDA/CLIA informational resources for more information on regulation and lists of cleared/approved tests (informational only).

FDA approval (informational)

FDA approval (informational)FDA approval or clearance of genetic tests is informational and not by itself a basis for coverage decisions.

Policy guidanceWhen deciding coverage, FDA-cleared/approved status may be referenced but coverage requires meeting medical necessity criteria and applicable contractual or InterQual requirements.

ResourcesPolicy provides FDA links listing cleared/approved nucleic-acid based tests and companion diagnostics for informational use.